Freising

FREISING, Germany, October 19, 2011 - -- Consortium Will Receive Six Million Euro from Seventh Framework Programme -- The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin therapeutic.

FREISING, Germany, October 19, 2011 - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris' proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding on its proprietary Anticalin pipeline.

FREISING, Germany, May 23, 2011 - - Data to be Presented at BioIron Society Meeting in Vancouver Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

FREISING, Germany, April 12, 2011 - Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets.

FREISING, Germany, April 11, 2011 - Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the Biotech Industry Conference 2011, to be held Friday, April 15, 2011 at the Millennium Broadway Hotel & Conference Center in New York, New York.